EBRC In Translation – Détails, épisodes et analyse

In this episode, we speak with Daniel Goodwin and Paul Reginato, the co-founders of Homeworld Collective, a non-profit working to support the social, intellectual, and funding infrastructure needed for climate biotech. Dan and Paul discuss the challenges in climate biotech, action-oriented optimism, their fast-grants program for climate research, how writing is a superpower, and so much more.

Later this year, Homeworld Collective will open a Garden Grants call for proposals on research in biotech and greenhouse gas removal. You can also learn about the latest in climate biotech by tuning into their podcast, the Climate Biotech Podcast, or by signing up for their newsletter through their website.

For more information about EBRC:

Visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!

Transcription:
Episode transcripts are the unedited output from Whisper and likely contain errors.

In this episode, we speak with Janice Chen, co-founder and CTO of Mammoth Biosciences. From her PhD work in Jennifer Doudna's lab to co-founding a biotech startup, Dr. Chen discusses her journey of translating scientific discoveries into real-world applications. Learn about the development of CRISPR-based diagnostics, including a rapid COVID-19 test, and gain insights into the evolving landscape of gene editing therapeutics. Dr. Chen also offers valuable advice for scientists looking to bridge the gap between academia and industry.

For more information about EBRC:

Visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!

Transcription:
Episode transcripts are the unedited output from Whisper and likely contain errors.

In this episode, we are joined by Dr. Mustafa Khammash, Professor of Control Theory and Systems Biology in the Department of Biosystems Science and Engineering at ETH-Zurich. We talk with Mustafa about integrating control theory into synthetic biology, designing computer/biology interfaces, starting a wet lab as a tenured computational professor, the need for new theoretical frameworks for biological design, and more!

Notes:

During the episode, Dr. Khammash references two different papers from his lab, linked below.

Cybergenetics: Theory and Applications of Genetic Control Systems

Universal structural requirements for maximal robust perfect adaptation in biomolecular networks

For more information about EBRC:

Visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!

Transcription:
Episode transcripts are the unedited output from Whisper and likely contain errors.

In this episode we’re joined by Eldora Ellison, PhD, director at law firm Sterne Kessler and lead patent strategist for the CVC group in the MIT-Berkeley CRISPR patent litigation. We discuss the long and winding road of filing and defending patents, what it’s like to go from PhD scientist to law firm partner, how biotechnology advances are challenging the world of patents, and more!

Links related to the episode:
Careers at Sterne Kessler
U.S. Biotechnology Patent Law by Jorge Goldstein

For more information about EBRC:

Visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!

Transcription:
Episode transcripts are the unedited output from Whisper and likely contain errors.

In this episode, we interview Vineeta Agarwala, MD, PhD, a general partner at Andreesen Horowitz (a16z) where she leads investments in the group’s bio + health fund. We talk to Vineeta about investing in synthetic biology startup companies, a day in the life of a VC, following the good people, and more!

Disclosures:

The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.

Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

For more information about EBRC:

Visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!

Transcription:
Episode transcripts are the unedited output from Whisper and likely contain errors.

In this episode, we interview Dr. Henry Lee, CEO of Cultivarium, a focused research organization that aims to expand access to novel microorganisms. We discuss the world’s fastest-growing bacterium, the challenges of domesticating non-model microbes, new organizational models for science, robotic dogs, and more!

If you are interested in Cultivarium, you can learn more and get involved at https://www.cultivarium.org/.

For more information about EBRC:

Visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!

Transcription:
Episode transcripts are the unedited output from Whisper and likely contain errors.

In this episode, we interview Dr. Doug Friedman, CEO of the BioIndustrial Manufacturing and Design Ecosystem (BioMADE) and President of the Engineering Biology Research Consortium (EBRC). We talk about how to build and grow community-driven organizations, what it takes to be an expert in DC, visions for the future of the bioeconomy, and more!

For more information about EBRC:

Visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!

Transcription:
Episode transcripts are the unedited output from Whisper and likely contain errors.

In this episode, we interview Dr. Hana El-Samad, a Professor at UCSF, editor-in-chief of GEN biotechnology, and a founding PI at Altos labs, whose research focuses on controlling mammalian cell behavior with genetic circuits. We talk with Dr. El-Samad about her work on controlling mammalian cell behavior, her role at and transition to Altos labs, committing to equity in STEM, the mission of GEN biotechnology, and more!

Notes and links:
Fund Black Scientists
Director Lander, the time is now

For more information about EBRC:

Visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!

Transcription:
Episode transcripts are the unedited output from Whisper and likely contain errors.

In this episode, we interview Dr. Ross Cloney, a Senior Editor at Nature Communications, focusing on the areas of synthetic biology, genome engineering, and therapeutic biotechnology. We talk with Ross about: how a manuscript becomes a publication; what it’s like to be an editor; how to make scientific publishing more diverse, equitable, and inclusive; what the future of scientific journals looks like; and more!

For more information about EBRC:

Visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!

Transcription:
Episode transcripts are the unedited output from Whisper and likely contain errors.

In this episode, we interview Dr. Doug Densmore, a professor at Boston University and co-founder of Lattice Automation, Asimov. and Biosens8. We talk to Doug about developing laboratory workflows as a service for engineering biology, finding your own management style, and treating automation and algorithms as first-class scientific citizens.

Links and notes for the episode:
Lynn Doucette-Stamm Runs the BU COVID testing facility
Programming Biology
Stem Pathways
Asimov
Lattice
biosens8
International Workshop on Bio-Design Automation
EBRC SPA Mentorship Program

For more information about EBRC:

Visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today!

Transcription:
Episode transcripts are the unedited output from Whisper and likely contain errors.